Various carrier system(s)- mediated genetic vaccination strategies against malaria (Q37150329)

18 August 2017

1 reference

retracted paper

3 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

PubMed

https://github.com/jmillanacosta/retractable/blob/e28dcac33244e89948fe17fb65f09b59e2ed804d/data/PMIDS_DOIS.csv

title

Various carrier system(s)- mediated genetic vaccination strategies against malaria (English)

1 reference

18 August 2017

0 references

Rajeev K Tyagi

1

1 reference

18 August 2017

Pradeep Kumar Sharma

series ordinal

2

1 reference

18 August 2017

Suresh P Vyas

series ordinal

3

1 reference

18 August 2017

Abhinav Mehta

series ordinal

4

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Expert Review of Vaccines

18 August 2017

published in

1 reference

18 August 2017

volume

7

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

499-520

1 reference

Malaria vaccines. Evaluation and implementation

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Progress towards the development of malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Naturally acquired immunity to Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Child mortality and malaria transmission intensity in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A review of human vaccine research and development: malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Dynamics of anti-VAR2CSA immunoglobulin G response in a cohort of senegalese pregnant women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Plasmodium vivax malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Pre-erythrocytic malaria vaccines: towards greater efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Vaccine-induced immunity to malaria parasites and the need for novel strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Common west African HLA antigens are associated with protection from severe malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Immune effector mechanisms in malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium y

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Plasmodium falciparum: D260, an intraerythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Interallelic recombination in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Malaria transmission-blocking vaccines--how can their development be supported?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Adjuvants designed for veterinary and human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Cation Permeability of Phospholipid Model Membranes: Effect of Narcotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Topical application of plasmid DNA to mouse and human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Anionic liposomal delivery system for DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Virosomal adjuvanted antigen delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Immunostimulating reconstituted influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Role of repetitive antigen patterns for induction of antibodies against antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Microparticle-based technologies for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Topical vaccination of DNA antigens: topical delivery of DNA antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Liposomes as immunological adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.499

Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Drug resistance in malaria

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Immunization of man against sporozite-induced falciparum malaria

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Malaria vaccines 1985-2005: a full circle?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Ca2+-ATPases and their expression in the mammary gland of pregnant and lactating rats

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

¿Debe regresar el uso del DDT para el control de vectores de la malaria?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1586/14760584.7.4.499

Identifiers

DOI

10.1586/14760584.7.4.499

1 reference

18 August 2017

1 reference